Global Hereditary Angioedema Market Size By Type (C1 Esterase Inhibitor, Kallikrein Inhibitor), By Application (Retail Pharmacies, Hospital Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Hereditary Angioedema (HAE) Market was valued at USD 2.4 billion in 2023 and is projected to reach USD 6.7 billion by 2031, growing at a CAGR of 13.6% during the forecast period from 2023 to 2031. The market growth is propelled by increased awareness of rare diseases, improved diagnostic capabilities, and the emergence of novel and targeted therapies. Hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling, has seen advancements in both prophylactic and on-demand treatment options, fueling significant market expansion globally.

Drivers:

1. Increased Diagnosis and Awareness of Rare Diseases:

Public health initiatives and patient advocacy groups are enhancing awareness and early diagnosis of HAE, which historically was underdiagnosed. This is contributing to higher treatment uptake.

2. Introduction of Targeted Biologic Therapies:

Innovations such as kallikrein inhibitors and monoclonal antibodies have revolutionized the HAE treatment landscape. The approval of long-term prophylactic therapies like lanadelumab and berotralstat are key drivers.

3. Expanding Access to Orphan Drug Designations and Reimbursement Policies:

Governments and regulatory bodies are incentivizing R&D for rare diseases through orphan drug designations, expedited approvals, and pricing support—encouraging pharmaceutical investment in the HAE market.

Restraints:

1. High Cost of Treatment:

HAE therapies, especially biologics, are expensive, making them less accessible in cost-sensitive markets. Despite insurance coverage, out-of-pocket expenses remain a challenge for patients in several countries.

2. Limited Awareness in Developing Economies:

While diagnosis rates are improving in developed nations, many low- and middle-income countries still lack the awareness and infrastructure necessary for proper diagnosis and treatment of HAE.

Opportunity:

1. Pipeline Expansion and Emerging Therapies:

Numerous companies are investing in next-generation treatments with better efficacy, administration routes (oral & subcutaneous), and longer half-lives. The evolving pipeline is set to create breakthrough opportunities.

2. Geographic Expansion in Underserved Markets:

The Asia-Pacific and Latin American regions offer untapped potential. With improving healthcare infrastructure and increasing focus on rare diseases, market players can expand their footprint in these regions.

Market by Treatment Type Insights:

The Prophylactic Treatment segment accounted for the largest market share in 2023, driven by a growing preference for preventive care to reduce HAE attack frequency. Therapies such as lanadelumab (Takhzyro) and berotralstat (Orladeyo) have gained significant traction due to their effectiveness and convenience of use. The On-demand Treatment segment is also witnessing steady growth, especially in emergency and hospital settings, with C1-inhibitor therapies and bradykinin B2 receptor antagonists widely adopted.

Market by Route of Administration Insights:

The Subcutaneous route emerged as the dominant segment in 2023, owing to improved patient compliance, reduced infusion times, and favorable safety profiles. However, the Oral segment is projected to grow at the highest rate, driven by innovations like berotralstat, which offers non-invasive daily treatment options for HAE patients.

Market by Regional Insights:

North America led the global hereditary angioedema market in 2023, supported by high disease awareness, well-established reimbursement systems, and robust R&D activities. Europe also held a substantial market share, especially in countries with strong rare disease healthcare frameworks. The Asia-Pacific region is expected to witness the fastest growth, propelled by increased healthcare investment, better access to diagnostics, and market entry of global players.

Competitive Scenario:

Key companies operating in the Global Hereditary Angioedema Market include Takeda Pharmaceutical Company Limited, BioCryst Pharmaceuticals, Pharming Group NV, CSL Behring, and Ionis Pharmaceuticals. These companies are focusing on drug development, regulatory approvals, partnerships, and regional expansion.

Key Developments:

In 2023, BioCryst’s Orladeyo witnessed expanded reimbursement approvals across multiple EU countries.

In 2024, CSL Behring initiated Phase III trials for a next-generation C1-inhibitor aimed at subcutaneous administration.

In 2025, Takeda launched a patient-support program in Asia-Pacific to promote early diagnosis and continuous treatment.

Scope of Work – Global Hereditary Angioedema Market

Report Metric Details

Market Size (2023) USD 2.4 billion

Projected Market Size (2031) USD 6.7 billion

CAGR (2023–2031) 13.6%

Market Segments Treatment Type, Route of Administration, Region

Growth Drivers Rise in rare disease awareness, emergence of biologic therapies

Opportunities Oral therapies, market expansion in Asia-Pacific and Latin America

FAQs:

1) What is the current market size of the Global Hereditary Angioedema Market?

The market was valued at USD 2.4 billion in 2023.

2) What is the major growth driver of the Global Hereditary Angioedema Market?

The major growth driver is the rise in diagnosis rates and the introduction of targeted biologic therapies.

3) Which is the largest region during the forecast period in the Global Hereditary Angioedema Market?

North America holds the largest market share due to advanced healthcare infrastructure and high awareness.

4) Which segment accounted for the largest market share in the Global Hereditary Angioedema Market?

The prophylactic treatment segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Hereditary Angioedema Market?

Key players include Takeda Pharmaceutical, BioCryst Pharmaceuticals, CSL Behring, Pharming Group NV, and Ionis Pharmaceuticals.